Skip to main content
. 2022 Jan 27;14(1):140–157. doi: 10.4254/wjh.v14.i1.140

Table 3.

Adoptive cell therapy for hepatocellular carcinoma

Adoptive cell transfer
Agent
Type of study
Study details
Outcome
NK cells stimulated with IL-2[60] Phase I trial Patients with liver cirrhosis with HCC undergoing liver transplantation Upregulation of peripheral NK cell cytotoxicity, no adverse events
CIK cell therapy as adjuvant to RFA[61] A multicenter, randomized, open label phase III trial 230 HCC patients; CIK cell therapy as adjuvant to RFA, ethanol injection or curative resection An improvement of 14 mo in recurrence free survival
Autologous TILs[62] Phase I trial 15 patients with HCC post-resection Successful expansion of TILs in 88% without any evidence of disease; No serious adverse events
GPC3 CAR-T[63] Phase I trial 13 Chinese patients with r/r GPC3+ HCC Feasible and safe for Chinese pts with r/r GPC3+ HCC; Promising antitumor potential when LDC is applied along with GPC3 CAR-T

NK: Natural killer; IL: Interleukin; HCC: Hepatocellular carcinoma; CIK: Cytokine-induced killer; TIL: Tumor-infiltrating lymphocytes; RFA: Radiofrequency ablation; CAR: Chimeric antigen receptor.